Epicentrx, Inc.

Itherx Pharmaceuticals Inc.

Ksc Industries Incorporated

Itherx Pharma, Inc.

Christopher Larson

Bryan T Oronsky

Tony R Reid

Robert W Sullivan

Antonio Garrido Montalban

Justin T Ernst

Zhijun Wang

Edward Roberts

Russell Dahl

Hiroshi Nakanishi

Jeffrey Dean Kahl

Erik Boman

Susana Conde Ceide

Nancy G J Delaet

Eddine Saiah

Zhinjun Wang

Stephen F Miller

Dean Menchaca Rivera

Farah Hedjran

Stephen Miller

Robert Sullivan

Jeffrey D Kahl

Antonio G Montalban

Justin Ernst

Susana Conde-Ceide

The invention provides for a recombinant adenoviral vector comprising a recombinant oncolytic adenovirus which has: (1) a modified transcription regulatory sequence wherein the adenoviral vector is transcriptionally active in cancer cells and/or hyperproliferative cells and transcriptionally attenuated in normal cells, and (2) a transgene encoding one or more cancer antigens that are specific to a subject. The invention further provides a method of producing said recombinant adenoviral vector. The recombinant oncolytic adenoviral vector described above is used in methods of stimulating a heightened immune response against a cancer antigen in a subject or a method of treating cancer in a subject.

Personalized cancer vaccines

The present disclosure relates to compositions and methods for producing a recombinant virus, e.g., a recombinant oncolytic adenovirus, using an A549 host cell.

A549 host cells comprising a recombinant oncolytic adenovirus with modified E1A cancer-specific promoter

Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site.

Recombinant adenoviruses carrying transgenes

Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGFβ trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

Immunomodulatory fusion proteins

The invention relates to a recombinant adenovirus comprising two or more therapeutic transgenes, e.g., two components of a heterodimeric cytokine, separated by a cleavable linker.

Multiple transgene recombinant adenovirus

The invention relates to a method for producing a recombinant virus, e.g., a recombinant oncolytic adenovirus, using an A549 host cell.

Method for producing recombinant oncolytic adenovirus with modified E1a cancer-specific promoter

Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

Human IL-10 receptor alpha fusion proteins

Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGF&#x3b2; trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines such as arthritis.

Cytokine inhibitors

Alpha-ketoamides and derivatives thereof

An electro-acoustic transducer for driving a large surface is used to convert electrical signals into sound. The transducer has a housing with a cast aluminum bottom and a molded plastic top. The top and bottom are fastened together by screws with a gasket in between the contacting surfaces to form a housing for a high power electromagnetic voice coil driver mechanism. The top has an opening to allow the voice coil to be centered in its gap by a centering gauge during assembly of the driver. A cap closes the opening once the voice coil is fixed in place in the housing. The op is hexagonal and flat with circular rings in the top surface to allow the top to flex in a controlled manner while supporting the bottom which remains stationary.

Growing community of inventors

San Diego, CA, United States of America

Christopher Larson